<DOC>
	<DOCNO>NCT01911169</DOCNO>
	<brief_summary>Determine effect vitamin D repletion flow mediate dilation ( FMD , measure endothelial function ) vitamin D deficient systemic lupus erythematosus ( SLE ) patient . The investigator enroll vitamin D deficient SLE patient randomize receive either 400 IU 5,000 IU cholecalciferol ( D3 ) daily measure change FMD measure EC function baseline 16 week repletion . Determine mechanisms vitamin D repletion may improve endothelial function vitamin D deficient SLE patient vitro . Determine effect oral D3 repletion Type I interferon signature WISH ECs culture pre post plasma D3 treat lupus patient . Determine effect D3 repletion number circulate apoptotic non-apoptotic EC EPC ex vivo . Determine effect exogenous 1,25 ( OH ) D IFN gene signature WISH ECs stimulate pretreatment SLE plasma vitro . Determine effect exogenous 1,25 ( OH ) D phenotype ECs culture pretreatment lupus plasma . This study design efficiently test hypothesis begin define interferon-dependent pathway vitamin D repletion restore clinical vitro endothelial function .</brief_summary>
	<brief_title>Vitamin D Improve Endothelial Function SLE</brief_title>
	<detailed_description>Specific Aim 1 . Determine effect vitamin D repletion change flow mediate dilation ( FMD ) vitamin D deficient SLE patient . The investigator hypothesize 25 ( OH ) D repletion improve endothelial function 25 ( OH ) D deficient lupus patient . For pilot study , investigator opt use Randomized Phase II screen design ( 36 ) . The screening design mean provide preliminary comparison experimental treatment appropriate control , idea pilot study would provide valuable information aid design definitive Phase III evaluation , experimental treatment prove promise Phase II trial . The trial design determine effect vitamin D repletion D3 FMD vitamin D deficient SLE subject . Approximately 50 SLE subject screen total 25 ( OH ) vitamin D ( 25 ( OH ) D ) level inclusion/exclusion criterion . However , screen continue 32 participant enrol total serum 25 ( OH ) vitamin D level â‰¤ 20 ng/ml meet inclusion/exclusion criterion . A baseline FMD , interferon ( IFN ) signature assay , level circulate non- apoptotic endothelial cell ( EC ) endothelial progenitor cell ( EPC ) perform baseline visit . Participants randomize two equal group 16 receive one two daily oral D3 dose previously use supplementation trial evidence harm . Group 1 ( control ) receive 400 international unit ( IU ) D3 daily . Group 2 receive 5,000 IU daily . Studies supplementation subject deficient vitamin D demonstrate supplementation 1,000 , 5,000 , 10,000 IU daily result increase 25 ( OH ) D 4.8 , 36.7 , 63.8 ng/mL without evidence toxicity ( 37 ) . In study , steady state level achieve 90 day . As show preliminary study , 4,000 IU daily safe effective repletion lupus clinic population . Some subject achieve steady state 90 day , invesitgators choose dose 16 week . The primary endpoint change FMD 16 week vitamin D repletion . The secondary endpoint reduction IFN signature level circulate apoptotic ECs/EPCs response vitamin D repletion baseline 16 week . Specific Aim 2 . Determine mechanisms vitamin D repletion may improve endothelial function vitamin D deficient SLE patient vitro . 2.1 Determine effect oral vitamin D3 repletion Type I interferon signature WISH ECs culture pre post plasma D3 treat lupus patient . The investigator hypothesize plasma-induced IFN gene signature reduce 25 ( OH ) D repletion . 2.2 Determine effect D3 repletion number circulate apoptotic non-apoptotic EC EPC ex vivo . The investigator hypothesize D3 repletion reduce number apoptotic EC EPC increase number non-apoptotic EPC association improve FMD . 2.3 Determine effect exogenous 1,25 ( OH ) D IFN gene signature WISH ECs stimulate pretreatment SLE plasma vitro . This aim design address specific question whether effect vitamin D least partially due direct rather indirect effect endothelial response SLE plasma IFN . 2.4 Determine effect exogenous 1,25 ( OH ) D phenotype ECs culture pretreatment lupus plasma . This aim design probe functional significance vitamin D repletion reduction IFN response endothelial phenotype .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Diagnosis SLE per 1997 American College Rheumatology Criteria ( least 4 criterion present ) Documented Vitamin D deficiency Able give inform consent Using tobacco product Pregnant/Planning pregnancy Known Hypercalcemia ( Serum Ca &gt; 10.4 ) Known Hypercalcuria ( Calcium/Creatinine &gt; 0.8 ) Chronic active lupus nephritis end stage renal disease kidney stone Known Hyperparathyroidism Known chronic viral/mycobacterial infection Uncontrolled medical disease Pl judgment Current drug alcohol abuse Anticipated poor compliance/known neuropsychiatric disorder Hx cardiovascular event ( i.e . Ml , PVD , CVE ) Subjects taking medication know affect FMD lupus subject limited fish oil , statin , remain stable dos throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>flow mediate dilation</keyword>
	<keyword>interferon gene signature</keyword>
</DOC>